How much does Poland have to pay Pfizer? Dispute over 6 billion zlotys

Pfizer is demanding approximately 5.6–6 billion zlotys from Poland for uncollected COVID-19 vaccine doses. Currently, the government has filed an appeal against the unfavorable court ruling in this case. The dispute over these funds represents one of the most costly challenges for the State Treasury in recent years, engaging the government's legal resources in a fight to renegotiate obligations incurred at the peak of the global health crisis.

Genesis of the conflict: Why is Pfizer suing Poland?

The legal dispute between Warsaw and the American pharmaceutical giant was initiated in January 2026. At that time, the case reached the court docket, immediately becoming a subject of interest for both the public and budget analysts. The foundation of the claims remains multilateral purchase agreements for preparations, the content of which obliged European Union member states to collect specific batches of goods. During the period of the pandemic's greatest momentum, when the priority was to secure supplies for citizens, contractual mechanisms were based on rigid delivery schedules.

The changing epidemiological reality after 2023 drastically reduced the demand for vaccines. Poland, like other countries in the region, faced a logistical and financial problem: how to fulfill contracts that had become inadequate to the health needs of society. Pfizer, relying on contractual provisions, considered the failure to collect batches a breach of contract, which led to taking the case to court. In February 2026, industry media, such as Mgr.farm, emphasized that the essence of the dispute is not a question of the quality or effectiveness of the preparations, but the pure execution of commercial provisions.

The company's strategy is based on the assumption that the risk associated with securing production and logistics during the pandemic was shifted to the buyer. In turn, Polish authorities argue that extraordinary circumstances and changes in the market situation should form the basis for adjusting the original arrangements. The lack of an agreement led to an escalation, which culminated in a court ruling of the first instance ordering the state to pay funds oscillating in the range of 5.6–6 billion zlotys.

Court ruling: A key defeat for the State Treasury

April 2026 brought a breakthrough decision that put Polish public finances in a difficult situation. The court of the first instance ruled in favor of Pfizer, confirming the validity of the pharmaceutical giant's claims. The amount of 6 billion zlotys represents an expenditure of enormous significance on the scale of the state budget, sometimes exceeding annual expenditures on the modernization of entire healthcare sub-sectors. Media, including "Rzeczpospolita", pointed to the weight of this ruling not only in financial terms but also legal ones, as a precedent in state-supplier relations in extraordinary situations.

For the State Treasury, this ruling was a signal for the immediate mobilization of the Ministry of Health's legal structures. The loss before the court of the first instance forced the government to revise its existing line of defense. Instead of accepting the claims, the ministry decided to initiate an appeal procedure. Each day of delay in a final resolution increases uncertainty regarding the final shape of financial obligations. The court in this process must decide whether contractual provisions drawn up under the conditions of "force majeure" of the pandemic retain full binding force under conditions of stabilization of the healthcare system.

It is worth noting that the scale of the financial demands caused technical issues – such as payment deadlines or contractual penalties – to take a back seat to the debate about responsibility for signing "take-or-pay" type contracts. This mechanism forces the buyer to pay for the ordered batch of goods, even if they decide not to collect it. It was this provision that became the main weapon in the hands of Pfizer's lawyers during the hearings before the court of the first instance. The Polish side is trying to demonstrate that the execution of this provision under current conditions is contrary to the principles of social coexistence, although in judicial practice, this is an extremely difficult argument to push through against a multinational corporation.

Government strategy: Appeal and the fight for the budget

The government did not accept the April ruling as a final verdict. Filing an appeal in August 2026 confirmed the determination of the current authorities regarding the minimization of budget losses. The Ministry of Health argues that protecting public finances requires exhausting all available legal paths. This strategy is not limited only to denying the claims but also includes an attempt to demonstrate errors in the interpretation of the contract by the lower court.

In the public sphere, the discussion focuses on whether dragging out the process is actually the best path for the taxpayer. On one hand, the appeal opens the way to changing the ruling; on the other, it exposes the budget to accruing interest and legal costs. The Ministry of Health, facing billion-zloty claims, must maneuver between the need to show a fight for the state's interest and the risk of losing before a higher court, which would definitively close the path to recovering funds or avoiding payment.

Poland is not the only country facing such problems. Similar controversies surrounding vaccine contracts have appeared in various European capitals, however, the Polish case is unique due to the size of the amount and the intensity of the political dispute that accompanies it. The state's strategy currently consists of questioning the validity of contractual penalties in the context of a drastic drop in interest in vaccinations. The government aims to demonstrate that the supplier, possessing knowledge of global market saturation, should have shown greater flexibility in the process of renegotiating contracts.

Political consequences: Tusk versus PiS

Events in the courtroom since April 2026 have become an important element of the rivalry between the Civic Platform and Law and Justice. Prime Minister Donald Tusk, commenting on the ruling, directly pointed to the responsibility of politicians from the previous governing camp. The Prime Minister's argumentation, cited among others by the "Do Rzeczy" portal, is based on the thesis that it was the way contracts were negotiated during the pandemic that directly led to the current financial crisis.

The politicization of the dispute aims to shift the burden of responsibility for the billion-zloty claims. For the ruling camp, this is an argument in the debate about the quality of state management by their predecessors. From the perspective of Law and Justice, these actions are merely an attempt to shift the blame for unfavorable court rulings that have already been handed down under the current coalition. This political ping-pong is in full swing, while the legal case proceeds at its own slow pace.

This narrative is extremely effective in mobilizing the electorate, but it does not facilitate the state's legal situation. The court hearing the appeal must remain impartial, ignoring media accusations. As a result, while politicians trade blows in the media, State Treasury lawyers must convince the judges of their arguments, basing them solely on hard evidence and contractual provisions. The question of whether the first-instance ruling will be upheld remains open, and every subsequent hearing is analyzed through the prism of potential consequences for the state budget for 2027 and subsequent years.

What this means for you

The citizen, as the ultimate taxpayer, is directly interested in the finale of this dispute. The amount of 6 billion zlotys is the equivalent of huge investments in infrastructure or healthcare that could have been realized if these funds did not have to go to the pharmaceutical company's coffers. A potential loss by the state in the appellate court means that the budget will have to be reduced by this sum, which in practice may translate into the necessity of limiting expenditures in other key areas.

This situation shows the long-term effects of decisions made under crisis conditions. The lack of flexibility clauses in contracts with pharmaceutical giants, which the government is currently pointing out, has become a trap from which there is no easy way out. The taxpayer must reckon with the fact that the legal battle will be costly, regardless of its finale. Ultimately, the Pfizer case is a lesson regarding the risk that the state takes upon itself in relations with global corporations in the face of unpredictable threats.

Questions and answers

How much money exactly does Pfizer want?

The company is demanding that Poland pay an amount in the range of 5.6–6 billion zlotys for unused vaccine doses.

Is the case finally settled?

No. The court of the first instance issued a ruling unfavorable to the State Treasury, but the government has filed an appeal, which means that the legal proceedings are ongoing.

What exactly does the dispute concern?

The dispute concerns the failure to fulfill contracts for the supply of COVID-19 vaccines, which were signed during the pandemic and which Poland did not collect after the crisis phase subsided.

What are the government's main arguments in the appeal?

The government is trying to challenge the ruling by questioning the validity of Pfizer's claims in the context of changed health and market circumstances and by striving to protect public finances.

Does the case have a political dimension?

Yes. The dispute has become a flashpoint for conflict between the current government of Donald Tusk and Law and Justice, with both sides blaming each other for the terms of contracts concluded during the pandemic.